Affymetrix, Exiqon, Max Planck Society, Rockefeller University, OGT, CapitalBio, Clinical Data | GenomeWeb
Affy Internal Audit Reveals ‘Lapses’ in Stock Option Grant Documentation
 
Affymetrix disclosed this week that its board of directors’ audit committee has been conducting an internal review of its stock option grant practices from Jan. 1, 1997, through May 31, 2006. This review has revealed “certain documentation lapses” in that period, “including one instance where the company has determined that the option grant date should have been recorded differently,” Affymetrix said in a statement.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.